



11 - 22 May 2026

**Les Pensières Center for Global Health
Veyrier-du- Lac, France**

ADVAC is co-organised by the University of Geneva and the Fondation Mérieux with the co-sponsorship of:

- Coalition for Epidemic Preparedness Innovations (CEPI)
- European Centre for Disease Prevention and Control (ECDC)
- European & Developing Countries Clinical Trials Partnership (EDCTP)
- European Society for Paediatric Infectious Diseases (ESPID)
- Gates Foundation
- International Pediatric Association (IPA)
- Johns Hopkins Bloomberg School of Public Health
- World Health Organization (WHO)

GENERAL INFORMATION

Meeting Venue	Les Pensières Center Global Health, 74290, Veyrier-du-Lac, France +33 450 64 80 80 – contact@lespensieres.org
Hotels	Les Pensières (contact: see above) Hotel Catalpa 34 Av. d'Albigny, 74000 Annecy + 33 04 50 23 02 46
Organization Team	<ul style="list-style-type: none"> • University of Geneva: Flavie Faës/Biata Lysenko: advac@unige.org for questions on the course • Mérieux Foundation: Marianne Gojon Gerbelot/Kristina Ruze : advac-logistique@fondation-merieux.org for questions on logistics (transports/accommodation/flights)
Dates of Meeting	Monday 11th May (9:00 am) – Friday 22nd May 2026 (3:45 pm)
Catering	<ul style="list-style-type: none"> • Lunches and Dinners are provided from 10^h to 22nd of May at the Meeting venue. • Placed meals: during the lunches, speakers will be placed at 1 or 2 per table. Participants are free to sit wherever they like to discuss with the lecturers. • Some meals are upon registration: check course programme and make sure you register on time (onsite only) at Les Pensières Reception Desk! • Food waste: as we are very concerned about food waste, please inform Les Pensières Reception Team at least ½ day before in case you cancel your participation your meal.
Transports	<ul style="list-style-type: none"> • Complimentary Shuttle every day between Hotels and Meeting Venue (see planning onsite) • Public Transports: <ul style="list-style-type: none"> - Getting around by local bus: https://www.sibra.fr/ - French Railway company: https://www.sncf-connect.com/en-en/ - Swiss Railway company: https://www.sbb.ch/en - Flixbus: https://www.flixbus.co.uk/ • Taxis: please ask Les Pensières Reception Team

COURSE PROGRAMME

MONDAY 11 MAY 2026

8:30	Bus from hotels to Les Pensières		
9:00-9:15	Opening and Objectives of the course	Kamel Senouci , Director ADVAC, University of Geneva	Charles Mérieux conf. Room
9:15-09:30	Introduction	Sakurako Marchand , Knowledge Sharing Unit Manager, Mérieux Foundation	
9:30-9:40	Welcome and Logistic briefing	Sandra Angèle , Director, Les Pensières, Fondation Mérieux	
SESSION 1: THE VACCINE JOURNEY: FROM VACCINES TO VACCINATION & THE IMPACT OF VACCINES			<u>Chair:</u> Arnaud Didierlaurent , UNIGE
9:40-10:05	1. From Research to individual protection: The A-to-Z vaccine's journey	Arnaud Didierlaurent and Kamel Senouci , University of Geneva, Switzerland	Charles Mérieux conf. room
10:05-10:25	Discussion		
10:25-10:55	Break		Restaurant
10:55-11:20	2. Vaccines Preventable Diseases' Burden and Vaccines Impact on Public Health	Kamel Senouci , University of Geneva	
11:20-11:40	Discussion		
11:40-12:05	3. Where are we with vaccine-preventable diseases & immunization coverage worldwide: the state of the immunization	Kate O'Brien , WHO, Geneva	Charles Mérieux conf. room
12:05-12:25	Discussion		
12:25-12:35	Morning evaluations		
12:35-13:35	Lunch	(seated, please check the tables attributed to the speakers)	Restaurant + Ogobara Doumbo room
13:35-14:00	4. Measuring vaccination's impact in populations: Regulatory vs. Public Health Approach to Vaccine Clinical Trial Data	Brad Gessner , Independent expert	
14:00-14:20	Discussion		
14:20-14:45	5. Using vaccines to address a public health problem: the example of Polio eradication immunization strategy	Ananda Bandyopadhyay , Gates Foundation, USA	Charles Mérieux conf. room
14:45-15:05	Discussion		
15:05-15:30	6. GAVI model to support countries immunization program	Marta Tufet , GAVI	
15:30-15:50	Discussion		
15:50-16:00	Afternoon evaluations		
16:00-16:15	Group Picture	Meet Outside!	In the garden
16:15-16:45	Break		Restaurant
16:45-17:30	Meet your mentor		Check information boards
17:30-18:30	Self-presentation of participants (background, interests in life...)	Social Event	Nicole Mérieux room
18:30-20:00	Welcome Reception		Nicole Mérieux room + Terrasse
20:00	Bus to Hotels		

TUESDAY 12 MAY 2026

8:30 Bus from hotels to Les Pensières

SESSION 2: HOW VACCINES WORK?

Chair:
Kamel Senouci,
Director
ADVAC, UNIGE

09:00-09:25	7. How do vaccines protect? Immune effectors induced by vaccines: Antibodies, B and T cells, mucosal immunity	Christiane Eberhardt , University of Geneva, Switzerland	
09:25-09:45	Discussion		
09:45-10:10	8. How are vaccines' responses elicited? What a vaccinologist should know about the basic aspects of immunological responses	Christiane Eberhardt , University of Geneva, Switzerland	Charles Mérieux conf. room
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	9. How to use vaccines' platforms to tailor immune responses?	Arnaud Didierlaurent , University of Geneva, Switzerland	
11:25-11:45	Discussion		
11:45-12:10	10. Non-specific effects of vaccines	Nigel Curtis , The Royal Children's Hospital, Melbourne, Australia (online)	Charles Mérieux conf. room
12:10-12:30	Discussion		
12:30-12:40	Morning evaluations		
12:40-14:00	Lunch		Restaurant + O. Doumbo room
14:00-15:30	Interactive Session 1 and Q&A Variability of vaccine responses in the real world	Christiane Eberhardt , University of Geneva, Switzerland & Arnaud Didierlaurent , University of Geneva, Switzerland	Charles Mérieux
15:30-15:55	11. Immunological memory	Rafi Ahmed , Emory University, USA	
15:55-16:15	Discussion		Charles Mérieux
16:15-16:45	Break		Restaurant
16:45-17:10	12. Use and limitations of correlates of immunity in vaccinology	Adam Finn , University of Bristol, UK	Charles Mérieux
17:10-17:30	Discussion		

SESSION 3 – VACCINE TECHNOLOGY & MANUFACTURING (PART 1/3)

Chair: Arnaud
Didierlaurent

17:30-17:55	13. Vaccine market, market shaping and regional initiatives for vaccine production	Georgios Stathopoulos , WHO, Switzerland	Charles Mérieux
17:55-18:15	Discussion		
18:15-18:25	Afternoon evaluations		
18:25-19:15	Soccer, Karaoke, Mölkky, Pétanque....	Social Event	Outside
19:30-21:00	Refreshments and Dinner		Restaurant
21:00	Bus to Hotels		

WEDNESDAY 13 MAY 2026

8:30 Bus from hotels to Les Pensières

SESSION 3 – VACCINE TECHNOLOGY & MANUFACTURING (PART 2/3)

Chair: Arnaud Didierlaurent
± E. Erbeling,

09:00-09:25	14. Landscape in vaccine and immunization technologies- platform-production (include nasal vaccine)	Emily Erbeling (Independent expert)	
09:25-09:45	Discussion		Charles Mérieux conf. Room
09:45 -10:10	15. Concepts of Chemistry, Manufacturing, and Controls (CMC) for vaccines	Ozzie Berger, IAVI, USA	
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	16. From inception to regulatory submission	Rick Malley, Boston Children Hospital, USA	
11:25-11:45	Discussion		
11:45-12:10	17. The complexity of quality control in vaccine manufacturing	Philippe Juvin, Sanofi Pasteur, France	Charles Mérieux
12:10-12:30	Discussion		
12:30-12:40	Morning evaluations		
12:40-13:55	Lunch		Restaurant + O. Doumbo

SESSION 4 – VACCINE REGULATORY

Chair: E. Erbeling

13:55-14:20	18. The role of Regulatory Agencies, Issues and Challenges of submitting a dossier (including content of a dossier)	Marco Cavaleri, EMA, The Netherlands	Charles Mérieux Room
14:20-14:40	Discussion		
14:40-16:10	Small Group Exercise 1 (Part 1): Vaccine Regulatory 4 Groups: <ul style="list-style-type: none"> ○ 1. O. Berger & L. Jodar ○ 2. A. Didierlaurent & V. Gambillara-Fonck ○ 3. O. Rovira & N. Baylor ○ 4. M. Cavaleri & D. Boyce 	Norman Baylor, Biologics Consulting Group, US Ozzie Berger, IAVI, USA, Donna Boyce, Pfizer USA, Marco Cavaleri, EMA, Netherland, Arnaud Didierlaurent, UNIGE, Switzeland, Veronica Gambillara-Fonck, Pureos Bioventures, Switzerland, Luis Jodar (independent expert), Olga Rovira, Kontivax, Belgium.	Check Boards for groups + rooms' assignment
16:10-16:40	Break		Restaurant
16:40-16:55	Small Group Exercise 1 (Part 2): Debriefing	All groups	Charles Mérieux Room
16:45-18:15	Optional lecture: Interactive Session 2 From ideas to implementation - the realities of funding for vaccine research and development in the private sector	DCVMN and IFPMA members Please check group assignments on boards	Charles Mérieux Room + S.Mérieux
18:15-18:25	Afternoon evaluations		Charles Mérieux

Special lecture: THE 10th LAMBERT LECTURE

18:25-18:35	Introduction	Paul-Henri Lambert	
18:35-19:00	19. Immune Fitness	John S. Tsang, Yale University, USA	Charles Mérieux room
19:00-19:20	Discussion		
19:30-20:45	Dinner		
20:45	Bus to Hotels		

THURSDAY 14 MAY 2026

08:30 Bus from hotels to Les Pensières

SESSION 3 – VACCINE TECHNOLOGY & MANUFACTURING (PART 3/3)

Chair: Emily
Erbelding

09:00-09:25 **20. Delivering outbreaks vaccine in 100 Days: What does it take?** Joseph Simmonds-Issler, CEPI, UK

09:25-09:45 Discussion

09:45-10:45 **Interactive session 3 and Q&A**

Panelists:

Charles
Mérieux
Conf room

What can go wrong in vaccine development?

Rosane Cuber, Bio-Manguinhos, Brazil
Luis Jodar (independent expert)
Rick Malley, Boston Children Hospital, USA
Emily Erbelding (independent expert)
Adam Finn, University of Bristol, UK

10:45-11:00 Break

Restaurant

SESSION 5 – ASSESSING VACCINES IN CLINICAL TRIALS (Part 1/2)

Chair: Edwin
Asturias

11:00-11:25 **21. A to Z for vaccines clinical trials**

Romina Libster, Fundacion INFANT, Argentina

11:25-11:45 Discussion

11:45-12:10 **22. Clinical trials: an overview of issues to be considered**

Andrew Pollard, Oxford Vaccine Group, UK

Charles
Mérieux

12:10-12:30 Discussion

12:30 -12:40 Morning Evaluations

12:40-13:25 Lunch

Restaurant

13:25-13:50 **23. Introduction to statistical aspects of clinical trials**

Martha Nason, PATH, USA

13:50-14:10 Discussion

Charles
Mérieux

14:10-16:25 **Small Group Exercise 2: How to design, recruit volunteers for, and analyze the results of selected phase II trials**

7 Groups:

Group 1: S. Aureus: V. Gambillara & B. Gessner
Group 2: Ebola: M. Nason & R. Libster
Group 3: Dengue: N. Baylor & A. Durbin
Group 4: RSV: E. Asturias & K. Talaat
Group 5: Mpox: K. Johansen
Group 6: Typhoid conjugate vaccines: K. Senouci
Group 7: Coronavirus: E. Erbelding

Check Boards
for groups +
rooms'
assignment

16:25-16:55 Break

Restaurant

16:55-17:20 **24. Assessing herd protection and vaccine effectiveness (and use for licensure)**

John Clemens, International Vaccine Institute (IVI), Republic of Korea

17:20-17:40 Discussion

Charles
Mérieux

17:40-18:05 **25. Human Challenge Trials or other ways of assessing vaccine efficacy**

Chris Chiu, Imperial College London, UK

18:05-18:25 Discussion

Charles
Mérieux

18:25-18:35 Afternoon evaluations

18:45-20:00 Dinner

Restaurant +
O.Doumbo room

20:00 Bus to Hotels

FRIDAY 15 MAY 2026

08:30 Bus from hotels to Les Pensières

SESSION 6 – VACCINE SAFETY - ASSESSMENT OF ADVERSE EFFECTS

Chair: Kari Johansen

09:00-09:25 **26. How do vaccines cause adverse events?**
(Including Immune-mediated diseases) **Kawsar Talaat**, Johns Hopkins
Bloomberg School of Public Health, USA

09:25-09:45 Discussion

Charles
Mérieux
Conf room

09:45-10:10 **27. WHO Guidance on how to detect and manage safety issues** **Madhav Balakrishnan**, WHO, Switzerland

10:10-10:30 Discussion

10:30-11:00 Break

Restaurant

11:00-11:25 **28. Population-based post-licensure surveillance**
(including study methodology for signal validation and epi studies) **Kaatje Bollaerts**, P95, Belgium

11:25-11:45 Discussion

Charles
Mérieux

11:45-12:10 **29. Immunization safety, logistic and vaccine management in vaccination programs (CTC, VVM)** **Kamel Senouci**, University of Geneva

12:10-12:30 Discussion

12:30-12:40 Morning Evaluations

12:40-14:00 Lunch

Restaurant +
Ogobara Doumbo

SESSION 5 – ASSESSING VACCINES IN CLINICAL TRIALS (Part 2/2)

14:00-14:30 Mentoring

14:30-16:40 **Small group exercise 3:**
Vaccine trial Phase III planning, implementation, analysis of the study results

7 Groups:
Group 1: V. Gambillara
Group 2: M. Nason & R. Libster
Group 3: N. Baylor & A. Durbin
Group 4: E. Asturias & K. Talaat
Group 5: K. Johansen
Group 6: K. Senouci
Group 7: E. Erbeling

Check Boards for
groups + rooms'
assignment

16:40-16:50 Afternoon evaluations

16:50-17:20 Break

Restaurant

Special lecture: THE 18TH PLOTKIN LECTURE

17:20-17:25 **Introduction** **Edwin Asturias**, Children's Hospital Colorado, USA

17:25-17:50 **30. Advancing CMV Vaccine Strategies: From Bench to Bedside** **Sallie Permar**, Cornell University, USA

Charles
Mérieux

17:50-18:10 Discussion

18:30-20:00 Reception Dinner

Restaurant +
O. Doumbo

20:00 Bus to Les Pensières

SATURDAY 16 MAY 2026

08:30 Bus from hotels to Les Pensières

SESSION 7 - ETHICAL ISSUES

Chair: Kari Johansen, Public Health Agency, Sweden

09:00-09:25 **31. Applied ethics in immunization programs and practice** **Anuradha Rose**, Christian Medical College of Vellore, India

09:25-09:45 Discussion

Charles Mérieux conf room

09:45-10:10 **32. Principles, guidelines and frameworks for ethical considerations in clinical trials of vaccines** **Catherine Slack**, University of KwaZulu-Natal, South Africa

10:10-10:30 Discussion

10:30-10:50 Break

Restaurant

10:50-13:00 **Small group exercise 4:**
Ethical considerations in vaccine trials

Facilitators (7 Groups):

Edwin Asturias, Kari Johansen, Anuradha Rose, Louise Henaff, Catherine Slack, Martha Nason, Kawsar Talaat.

Check Boards for groups + rooms' assignment

13:00-13:10 Evaluations of the day

13:10-13:40 Lunch

Take away or eat at the Restaurant

13:40 Bus to Hotels and Free time in the afternoon

18:45 Bus from Hotels to Les Pensières

Dinner upon Registration

Please register at Les Pensières Lobby

Restaurant

20:15 Bus from Les Pensières to Hotels

SUNDAY 17 MAY 2026

18:45 Bus from hotels to Les Pensières (for dinner only)

Dinner upon registration

Please register at Les Pensières Lobby

Restaurant

20:15 Bus from Les Pensières to Hotel

MONDAY 18 MAY 2026

8:30	Bus from hotels to Les Pensières		
09:00-09:10	Ethical considerations in vaccine trials: Recap	Catherine Slack , University of KwaZulu-Natal, South Africa	Charles Mérieux conf. Room
SESSION 8 – DECISION MAKING FOR VACCINES (Part 1/2)			<u>Chair:</u> Louise Henaff
09:10-09:35	33. The decision-making processes for vaccines use: global, regional and local perspectives	Rudzani Muloiwa , University of Cape Town, South Africa	
09:35-09:55	Discussion		Charles Mérieux
09:55-10:20	34. The example of the WHO SAGE decision making processes	Melanie Marti , WHO Geneva, Switzerland	
10:20-10:40	Discussion		
10:40-11:10	Break		Restaurant
11:10-11:35	35. The decision-making processes for vaccines' use: what should experts consider	Kari Johansen , Public Health Agency of Sweden	
11:35-11:55	Discussion		
11:55-12:20	36. The role of health economics (including modelling) as a tool in analyzing vaccine policy options	Marc Brisson , Université de Laval, Canada	Charles Mérieux
12:20-12:40	Discussion		
12:40-12:50	Morning Evaluations		
12:50-13:50	Lunch		Restaurant
13:50-16:00	Small group exercise 5 Decision-making for the evaluation and impact assessment of new vaccines introduced in selected countries: safety and effectiveness.	7 Groups: <ul style="list-style-type: none"> • Group 1: Rotavirus: M. Iturriza • Group 2: HPV: K. Senouci • Group 3: Dengue LMICs: H. Nohynek • Group 4: Zoster: K. Johansen • Group 5: Malaria: K. Neuzil • Group 6: RSV Adults: K. Talbot • Group 7: RSV: J. Englund 	Check rooms' assignments on boards
16:00-16:20	Break		Restaurant
SESSION 9 – UPDATES ON VACCINES (part 1/4)			<u>Chair:</u> Anna Durbin
16:20-16:45	37. Polysaccharide and conjugate vaccines	David Goldblatt , University College London, UK (online)	
16:45-17:05	Discussion		
17:05-17:30	38. Pneumococcal conjugate vaccines: the impact of PCV, its introduction in different populations (including adults & children) and the change in PCV valency stereotypes	Keith Klugman , Gates Foundation, USA (online)	Charles Mérieux conf. Room
17:30-17:50	Discussion		
17:50-18:00	Afternoon evaluations		
18:00-19:00	Book your Mentor		
19:00-20:15	Dinner		Restaurant + O. Doumbo
20:15	Bus to Hotels		

TUESDAY 19 MAY 2026

08:30 Bus from hotels to Les Pensières

SESSION 9 – UPDATES ON VACCINES (part 2/4)

Chair: Anna Durbin

09:00-09:25	39. HPV vaccines	Deborah Watson-Jones , London School of Hygiene and Tropical Medicine & Mwanza Intervention Trials Unit (MITU) Tanzania	
09:25-09:45	Discussion		Charles Mérieux
09:45-10:10	40. Typhoid vaccines	Kathy Neuzil , Gates Foundation	conf. Room
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	41. Malaria Vaccines	Simon Draper , University of Oxford, UK	
11:25-11:45	Discussion		
11:45-12:10	42. Vaccines against arboviruses (Dengue, Zika, Chikungunya)	Anna Durbin , Johns Hopkins Bloomberg School of Public Health, USA	Charles Mérieux
12:10-12:30	Discussion		
12:30-12:40	Morning evaluations		
12:40-14:00	Lunch		Restaurant + O. Doumbo
14:00-14:25	43. Rotavirus and norovirus vaccines	Miren Iturriza , Gates Foundation	
14:25-14:45	Discussion		Charles Mérieux

SESSION 8 – DECISION MAKING FOR VACCINES (Part 2/2)

Chair: Anna Durbin

14:45-15:45	Small group exercise 6 Sharing recommendations with the Minister of Health	Restitution of the 7 Groups from Exercise 5	
			Charles Mérieux
15:45-16:15	Break		Restaurant

SESSION 9 – UPDATES ON VACCINES (part 3/4)

Chair: Anna Durbin

16:15-16:40	44. Annual strain adaptation: the examples of Flu and COVID vaccines	Kanta Subbarao , Université de Laval, Canada	
16:40-17:00	Discussion		
17:00-17:25	45. Combination vaccines	Hanna Nohynek , Finnish Institute for Health and Welfare, Finland	Charles Mérieux
17:25-17:45	Discussion		
17:45-18:10	46. Vaccines for Non-Communicable Diseases	Joachim Hombach , University of Geneva, Switzerland	
18:10-18:30	Discussion		
18:30 - 18:40	Afternoon evaluation		
18:40-19:10	Debate “Mandatory vs voluntary vaccination”	Rudzani Muloiwa & Kathy Neuzil	Charles Mérieux
19:10-20:30	Dinner		Restaurant + O. Doumbo
20:30	Bus to Hotels		

WEDNESDAY 20 MAY 2026

08:30 Bus from Hotels to les Pensières

SESSION 10 - SELECTING APPROPRIATE VACCINATION STRATEGIES

Chair: **Hanna Nohynek**

09:00-09:25	47. RSV and GBS vaccines	Janet Englund , University of Washington/Seattle Children's Hospital Seattle, USA	Charles Mérieux conf. Room
09:25-09:45	Discussion		
09:45-10:10	48. Vaccination and pregnancy and early life	Christiane Eberhardt , University of Geneva, Switzerland	Charles Mérieux
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	49. Vaccination schedules: Past, present and future - is there some rationale?	Edwin Asturias , Children's Hospital Colorado, USA	Charles Mérieux
11:25-11:45	Discussion		
11:45-12:10	50. Vaccine responses and efficacy in the elderly	Keipp Talbot , Vanderbilt University, USA	Charles Mérieux
12:10-12:30	Discussion		
12:30-12:55	51. Vaccination in immuno-compromised individuals	Christoph Berger , University of Basel, Switzerland	Charles Mérieux
12:55-13:15	Discussion		
13:15-13:25	Morning evaluations		
13:25-14:55	Lunch		Restaurant

15:00-16:30 PARALLEL SESSIONS (rotation of two 45 min-Sessions)

1. National decision-making for immunization programmes	Louise Henaff, Rudzani Muloiwa , Cape Town University	Check Board for Assignment into group exercises
2. Clinical vaccinology: from Guidelines to Patient Care	Alessandro Diana, Christiane Eberhardt , University Hospitals of Geneva (HUG)	
3. New approaches towards vaccination e-registries	Julia Stowe , UKHSA, UK, Carolina Danovaro , WHO Geneva, and Kari Johansen , Public Health Agency, Sweden	
4. Monitoring immunization program performance	Jan Grevendonk , WHO Geneva	
5. Global and regional data for Global Strategies	Laure Dumolard , WHO Geneva	
6. AEFI causality assessment	Madhav Balakrishnan , WHO, Geneva	

16:30-16:45 Break Restaurant

SESSION 11 – REACHING SPECIFIC GROUPS (part ½)

Chair: **Kamel Senouci**

16:45-17:10	52. How to better reach the zero-dose or under-vaccinated children in LMICs	Kamel Senouci , University of Geneva	Charles Mérieux conf. Room
17:10-17:30	Discussion		
17:30-17:40	Afternoon evaluations		
18:00-19:15	Dinner upon registration		Restaurant
19:15	Bus to Hotels		

THURSDAY 21 MAY 2026

08:30 Bus from hotels to Les Pensières

SESSION 9 – UPDATES ON VACCINES (Part 4/4)

Chair: Edwin Asturias

09:00-09:25	53. Cholera vaccines	Alejandro Cravioto , National Autonomous University of Mexico	
09:25-09:45	Discussion		Charles Mérieux
09:45-10:10	54. Meningococcal vaccines	Shamez Ladhani , UKHSA, UK	
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	55. Tuberculosis vaccines	Helen McShane , University of Oxford, UK	
11:25-11:45	Discussion		Charles Mérieux

SESSION 11 – REACHING SPECIFIC GROUPS (part 2/2)

Chair: Kamel Senouci

11:45-12:10	56. Life-course vaccines: how to better reach individuals from childhood to elderly?	Pierre Vandamme , University of Antwerp, Belgium (online)	
12:10-12:30	Discussion		Charles Mérieux
12:30-12:55	57. The determinants of vaccine acceptance	Eve Dubé , Université de Laval, Canada	
12:55-13:15	Discussion		
13:15-13:25	Morning evaluations		
13:25 – 14:25	Lunch		Restaurant + O.DUmbo

SESSION 12 – COMMUNICATION AND VACCINE HESITANCY (part ½)

14:25-15:25	Small group exercise 7: Identifying & Collecting Evidence to advise on demand generation	Eve Dubé, Naveen Thacker, Kamel Senouci, Louise Henaff, Rudzani Muloiwa, Angus Thomson	Several rooms: please check on boards
15:25-16:25	Interactive Session 4 and Q&A	Lucien De Brot and Darius Beucler , OPSCI, France	Charles Mérieux
16:25-16:35	Vaccination in the face of information chaos: from Analysis to Strategic Response		
16:25-16:35	Afternoon evaluations		
16:35	Break		Restaurant
16:45	Bus departure from les Pensières to hotels (check board for return bus from hotels to the Menthon Castle)		Meet at the Reception Lobby
18:15	Bus departure from Les Pensières to Château de Menthon Saint Bernard for visit of the castle and Gala Dinner		
22:00 and 23:45	Buses from Château de Menthon to les Pensières & Hotels		

FRIDAY 22 MAY 2026

08:30 Bus from hotels to Les Pensières

SESSION 12: COMMUNICATION AND VACCINE HESITANCY (part 2/2)

Chair:
Louise Henaff,

09:00-09:20	58. Introduction to Communication Strategy design	Louise Henaff, University of Geneva	Charles Mérieux conf. Room
09:20-10:30	Small Group Exercise 8: Communication strategy design	Lucien De Brot, Darius Beucler, Kamel Senouci, Louise Henaff, Eve Dubé, Naveen Thacker	Several rooms: check on boards
10:30-11:00	Break		Restaurant
11:00-11:25	59. Introduction to Empathetic Communication	Philipp Schmid, JITSUVAX, Netherlands	Charles Mérieux
11:25-12:30	Small Group Exercise 9: Empathetic Communication, Role play	Philipp Schmid, Eve Dubé, Alessandro Diana, Kamel Senouci, Louise Henaff, Rudzani Muloiwa, Angus Thomson	Several rooms: check on boards

SESSION 13: INNOVATION ON IMMUNIZATION

Chair:
Kamel Senouci

12:30-12:55	60. Artificial Intelligence and vaccines	Edwin Asturias, Children's Hospital Colorado, USA	Dr. Charles Mérieux conf. Room
12:55-13:15	Discussion		
13:15-13:25	Morning evaluations		
13:25-14:40	Lunch		Restaurant + O. Doumbo

SESSION 14: CLOSING

14:40-15:00	Final evaluation and Post course assessment		Charles Mérieux
15:00-15:45	Diploma ceremony, awarding of CME credits and closure of the course	Kamel Senouci, Director, ADVAC, University of Geneva	
16:30	Bus from Les Pensières to hotels (check boards for Schedule)		

OPTIONAL LECTURE

WEDNESDAY 13 MAY 2026

SESSION 3: VACCINE TECHNOLOGY, MANUFACTURING AND APPROVAL

Chair: Kamel Senouci, Director ADVAC, University of Geneva

16:45-18:15

Interactive Session 2

From ideas to implementation - the realities of funding for vaccine research and development in the private sector

Two 45-minutes sessions (2 groups switching)

Group A: starting with Fiocruz

Group B: starting with Luis Jodar

Luis Jodar, independent expert

Rosane Cuber, Bio-Manguinhos Brazil

Room Charles Mérieux

+

Room Nicole Mérieux